Midterm Outcomes of Pediatric Mitral Valvuloplasty for Moderate to Severe Mitral Valve Regurgitation and Associated Risk Factors for Postoperative Deterioration.

IF 0.9 4区 医学
Texas Heart Institute Journal Pub Date : 2025-07-30 eCollection Date: 2025-07-01 DOI:10.14503/THIJ-24-8523
Hongyuan Fu, Aijun Liu, Ming Yang, Zeyu Liu, Junwu Su
{"title":"Midterm Outcomes of Pediatric Mitral Valvuloplasty for Moderate to Severe Mitral Valve Regurgitation and Associated Risk Factors for Postoperative Deterioration.","authors":"Hongyuan Fu, Aijun Liu, Ming Yang, Zeyu Liu, Junwu Su","doi":"10.14503/THIJ-24-8523","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Mitral valvuloplasty is considered the best treatment for pediatric mitral valve regurgitation. The objective of this analysis was to identify risk factors for postoperative mitral valve regurgitation progression and evaluate valvuloplasty effectiveness.</p><p><strong>Methods: </strong>This retrospective, single-center study investigated the clinical efficacy of mitral valvuloplasty and identified factors that affect prognosis. Pediatric patients with moderate or severe mitral valve regurgitation who had undergone mitral valvuloplasty between September 2016 and August 2023 were included. Kaplan-Meier survival analysis was used to assess freedom from both mitral valve deterioration and cardiovascular death. Univariate and multivariate Cox regression analyses were performed to identify potential risk factors.</p><p><strong>Results: </strong>The study comprised 137 pediatric patients (mean age, 37.5 months [range, 2.4-167.6 months]) who had moderate (64/137 [46.7%]) or severe (73.137 [53.3%]) mitral valve regurgitation. At midterm follow-up (median, 55.3 months), mitral valve regurgitation had statistically significantly decreased compared with preoperative levels (<i>P</i> < .001, Wilcoxon signed-rank test); freedom from cardiovascular death was 97.5%, and freedom from worsening mitral valve regurgitation was 89.4%. Cox regression analysis identified body weight (<i>P</i> = .02), left ventricular end-diastolic diameter (<i>P</i> = .005), and left ventricular ejection fraction (<i>P</i> = .01) at 1 month and cardiopulmonary bypass time (<i>P</i> = .007) as independent risk factors for deterioration. Patients weighing 10 kg or more (<i>P</i> = .04) or with a ventricular septal defect 8 mm or larger (<i>P</i> = .04) had worse outcomes.</p><p><strong>Conclusion: </strong>Mitral valvuloplasty resulted in low mortality and positive long-term results in pediatric patients with mitral valve regurgitation. Early aggressive therapy is recommended to avoid late postoperative mitral valve deterioration.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"52 2","pages":"e248523"},"PeriodicalIF":0.9000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12310506/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Texas Heart Institute Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14503/THIJ-24-8523","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Mitral valvuloplasty is considered the best treatment for pediatric mitral valve regurgitation. The objective of this analysis was to identify risk factors for postoperative mitral valve regurgitation progression and evaluate valvuloplasty effectiveness.

Methods: This retrospective, single-center study investigated the clinical efficacy of mitral valvuloplasty and identified factors that affect prognosis. Pediatric patients with moderate or severe mitral valve regurgitation who had undergone mitral valvuloplasty between September 2016 and August 2023 were included. Kaplan-Meier survival analysis was used to assess freedom from both mitral valve deterioration and cardiovascular death. Univariate and multivariate Cox regression analyses were performed to identify potential risk factors.

Results: The study comprised 137 pediatric patients (mean age, 37.5 months [range, 2.4-167.6 months]) who had moderate (64/137 [46.7%]) or severe (73.137 [53.3%]) mitral valve regurgitation. At midterm follow-up (median, 55.3 months), mitral valve regurgitation had statistically significantly decreased compared with preoperative levels (P < .001, Wilcoxon signed-rank test); freedom from cardiovascular death was 97.5%, and freedom from worsening mitral valve regurgitation was 89.4%. Cox regression analysis identified body weight (P = .02), left ventricular end-diastolic diameter (P = .005), and left ventricular ejection fraction (P = .01) at 1 month and cardiopulmonary bypass time (P = .007) as independent risk factors for deterioration. Patients weighing 10 kg or more (P = .04) or with a ventricular septal defect 8 mm or larger (P = .04) had worse outcomes.

Conclusion: Mitral valvuloplasty resulted in low mortality and positive long-term results in pediatric patients with mitral valve regurgitation. Early aggressive therapy is recommended to avoid late postoperative mitral valve deterioration.

Abstract Image

Abstract Image

小儿二尖瓣成形术治疗中度至重度二尖瓣返流的中期结果及术后恶化的相关危险因素
背景:二尖瓣成形术被认为是治疗小儿二尖瓣反流的最佳方法。本分析的目的是确定二尖瓣术后返流进展的危险因素,并评估二尖瓣成形术的有效性。方法:回顾性、单中心研究二尖瓣成形术的临床疗效及影响预后的因素。纳入了2016年9月至2023年8月期间接受二尖瓣成形术的中度或重度二尖瓣返流的儿科患者。Kaplan-Meier生存分析用于评估二尖瓣恶化和心血管死亡的自由。进行单因素和多因素Cox回归分析以确定潜在的危险因素。结果:本研究纳入中度(64/137[46.7%])或重度(73.137[53.3%])二尖瓣反流患儿137例(平均年龄37.5个月[范围2.4-167.6个月])。中期随访(中位,55.3个月),与术前相比,二尖瓣返流明显减少(P < 0.001, Wilcoxon sign -rank检验);心血管死亡自由率为97.5%,二尖瓣返流恶化自由率为89.4%。Cox回归分析发现体重(P = 0.02)、左室舒张末期内径(P = 0.005)、1个月时左室射血分数(P = 0.01)和体外循环时间(P = 0.007)是病情恶化的独立危险因素。体重10 kg或以上(P = 0.04)或室间隔缺损8 mm或以上(P = 0.04)的患者预后较差。结论:二尖瓣成形术治疗小儿二尖瓣返流死亡率低,远期疗效良好。建议早期积极治疗,避免术后晚期二尖瓣恶化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Texas Heart Institute Journal
Texas Heart Institute Journal CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
11.10%
发文量
131
期刊介绍: For more than 45 years, the Texas Heart Institute Journal has been published by the Texas Heart Institute as part of its medical education program. Our bimonthly peer-reviewed journal enjoys a global audience of physicians, scientists, and healthcare professionals who are contributing to the prevention, diagnosis, and treatment of cardiovascular disease. The Journal was printed under the name of Cardiovascular Diseases from 1974 through 1981 (ISSN 0093-3546). The name was changed to Texas Heart Institute Journal in 1982 and was printed through 2013 (ISSN 0730-2347). In 2014, the Journal moved to online-only publication. It is indexed by Index Medicus/MEDLINE and by other indexing and abstracting services worldwide. Our full archive is available at PubMed Central. The Journal invites authors to submit these article types for review: -Clinical Investigations- Laboratory Investigations- Reviews- Techniques- Coronary Anomalies- History of Medicine- Case Reports/Case Series (Submission Fee: $70.00 USD)- Images in Cardiovascular Medicine (Submission Fee: $35.00 USD)- Guest Editorials- Peabody’s Corner- Letters to the Editor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信